ARVINAS, INC. - 8-K Filing
Arvinas and Pfizer received $70 million in upfront payments from Rigel Pharmaceuticals under a license agreement for VEPPANU (vepdegestrant) following HSR Clearance on June 11, 2026. The companies are also eligible to receive up to an additional $320 million through milestones and royalties. (Items: 8.01 Other Events)
Tickers: $ARVN